CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for ...
Donidalorsen (Dawnzera) received FDA approval for prophylactic treatment of hereditary angioedema (HAE) in adults and kids 12 years and older, Ionis Pharmaceuticals announced on Thursday. The ...
EAST HANOVER, N.J., Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido ® (remibrutinib) received US Food and Drug Administration (FDA) approval as an oral treatment for adult ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
PORTLAND, Ore., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the close of a $95 million Series B financing. The round ...
A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...
Late-stage biopharma Scholar Rock (SRRK) is approaching a pivotal catalyst: the FDA decision on apitegromab, its investigational muscle-targeted therapy for spinal muscular atrophy (SMA). A verdict is ...
HAE is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling (angioedema) in various parts of the body, including the hands, feet, genitals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback